{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?dateTabled=2023-02-01&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?dateTabled=2023-02-01&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?dateTabled=2023-02-01&_metadata=all&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&dateTabled=2023-02-01&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?dateTabled=2023-02-01&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?dateTabled=2023-02-01&min-ddpModified.=2023-02-07T17%3A31%3A12.118Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1582714", "AnsweringBody" : [{"_value" : "Cabinet Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582714/answer", "answerText" : {"_value" : "
The information requested falls under the remit of the UK Statistics Authority.<\/p>
<\/p>
A response to the Hon. Member's Parliamentary Question of 1 February is attached.<\/p>
<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4507", "label" : {"_value" : "Biography information for Sir Jeremy Quin"} } , "answeringMemberConstituency" : {"_value" : "Horsham"} , "answeringMemberPrinted" : {"_value" : "Jeremy Quin"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1582714/answer/attachment/1", "fileName" : {"_value" : "PQ137833.pdf"} , "title" : "UKSA Response"} , "dateOfAnswer" : {"_value" : "2023-02-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-02-09T17:11:59.787Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "53"} , "answeringDeptShortName" : {"_value" : "Cabinet Office"} , "answeringDeptSortName" : {"_value" : "Cabinet Office"} , "date" : {"_value" : "2023-02-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Mortality Rates"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Minister for the Cabinet Office, whether he has made an assessment of the adequacy of ONS data on excess deaths.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4638", "label" : {"_value" : "Biography information for Mr Tanmanjeet Singh Dhesi"} } , "tablingMemberConstituency" : {"_value" : "Slough"} , "tablingMemberPrinted" : [{"_value" : "Mr Tanmanjeet Singh Dhesi"} ], "uin" : "137833"} , {"_about" : "http://data.parliament.uk/resources/1582716", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582716/answer", "answerText" : {"_value" : "
The life sciences sector is among the most valuable and strategically important in the United Kingdom\u2019s economy. The latest edition of the Government\u2019s Life Sciences Competitiveness Indicators shows that in 2020, the UK ranked sixth out of 10 comparator countries for our share of patients recruited to a subset of commercial global studies for novel medicines. The UK also ranked seventh for the time taken between clinical trial application and first dose to first patient. This is up from tenth in 2019.<\/p>
The indicators also show that, in 2020, the UK pharmaceutical industry spent over £5 billion on research and development (R&D) and has consistently been the largest industry to spend on R&D in the UK, making up more than a fifth of all R&D performed by industry between 2014 and 2020.<\/p>
The National Health Service in England is internationally competitive in adopting innovative medicines. Industry data shows that there are five treatments available in England for every four in Europe and almost a third more cancer drugs.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"} } , "answeringMemberConstituency" : {"_value" : "Colchester"} , "answeringMemberPrinted" : {"_value" : "Will Quince"} , "dateOfAnswer" : {"_value" : "2023-02-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-02-09T13:56:52.207Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-02-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Manufacturing Industries"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of (a) the competitiveness of the UK pharmaceutical industry for (i) conducting clinical trials and (ii) research and development and (b) the impact of the level of use of innovative medicines in the NHS on outcomes for patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "137769"} , {"_about" : "http://data.parliament.uk/resources/1582719", "AnsweringBody" : [{"_value" : "Department for Energy Security and Net Zero"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582719/answer", "answerText" : {"_value" : "
The Department considers the impact of international policies on UK investment to ensure the Government meets its net zero and economic growth ambitions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1482", "label" : {"_value" : "Biography information for Graham Stuart"} } , "answeringMemberConstituency" : {"_value" : "Beverley and Holderness"} , "answeringMemberPrinted" : {"_value" : "Graham Stuart"} , "dateOfAnswer" : {"_value" : "2023-02-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-02-09T12:03:00.617Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "215"} , "answeringDeptShortName" : {"_value" : "Energy Security and Net Zero"} , "answeringDeptSortName" : {"_value" : "Energy Security and Net Zero"} , "date" : {"_value" : "2023-02-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Energy: Investment"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Energy Security and Net Zero, if he will make a comparative assessment of the competitiveness of the (a) UK and (b) US energy investment environment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "137771"} , {"_about" : "http://data.parliament.uk/resources/1582720", "AnsweringBody" : [{"_value" : "Department for Energy Security and Net Zero"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582720/answer", "answerText" : {"_value" : "
The Department considers the impact of international policies on UK investment to ensure the Government meets its net zero and economic growth ambitions.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1482", "label" : {"_value" : "Biography information for Graham Stuart"} } , "answeringMemberConstituency" : {"_value" : "Beverley and Holderness"} , "answeringMemberPrinted" : {"_value" : "Graham Stuart"} , "dateOfAnswer" : {"_value" : "2023-02-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-02-09T12:03:52.263Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "215"} , "answeringDeptShortName" : {"_value" : "Energy Security and Net Zero"} , "answeringDeptSortName" : {"_value" : "Energy Security and Net Zero"} , "date" : {"_value" : "2023-02-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Energy: Investment"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Energy Security and Net Zero, if he will make a comparative assessment of the competitiveness of the (a) UK and (b) EU energy investment environment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"} } , "tablingMemberConstituency" : {"_value" : "Strangford"} , "tablingMemberPrinted" : [{"_value" : "Jim Shannon"} ], "uin" : "137772"} , {"_about" : "http://data.parliament.uk/resources/1582721", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582721/answer", "answerText" : {"_value" : "
Funding for 2022/23 has been made available for that financial year only.<\/p>
As set out in the Urgent and Emergency Care Recovery Plan, the Government has committed to targeted funding to support services next year. This includes £1 billion to support hospitals to increase capacity in 2023/24; and £1.6 billion of additional social care discharge funding over 2023/24 and 2024/25.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"} } , "answeringMemberConstituency" : {"_value" : "Colchester"} , "answeringMemberPrinted" : {"_value" : "Will Quince"} , "dateOfAnswer" : {"_value" : "2023-03-06", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-03-06T16:54:59.707Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-02-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Finance"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to allow funding provided to ease winter pressures in the NHS in the 2022-23 financial year to be used for winter planning for the 2023-24 financial year.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4471", "label" : {"_value" : "Biography information for Rachael Maskell"} } , "tablingMemberConstituency" : {"_value" : "York Central"} , "tablingMemberPrinted" : [{"_value" : "Rachael Maskell"} ], "uin" : "137835"} , {"_about" : "http://data.parliament.uk/resources/1582723", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1582723/answer", "answerText" : {"_value" : "
The UK implementation of the Pillar 2 Global Minimum Tax was scored at Autumn Statement 2022.<\/p>
<\/p>